Loading...
NPI 1831898089 · Arvada, CO · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Keystone Labs LLC is a clinical medical laboratory provider located in Arvada, Colorado. This profile covers 16 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Keystone Labs LLC |
| Address | 9122 W 88th Ave |
| City | Arvada |
| State | CO |
| ZIP | 80005 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | February 27, 2023 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.6M |
| Medicaid | $190 |
The provider’s Medicare revenue is heavily concentrated in three codes: K1034 (62.7% of Medicare revenue), 81440 (11.5%), and 81443 (8.5%), and those top 3 Medicare codes together account for 82.7% of this provider’s total Medicare revenue. This mix signals a dual service line: very high-volume COVID self-test provision (K1034, with low average payment per claim) alongside targeted, high-dollar genomic panels (81440 and 81443) that generate substantial revenue per claim despite low claim counts.
K1034 is the single largest Medicare driver with $990.4K revenue and 82.5K claims at $12 avg paid/claim; despite ranking #180 of 30143 providers nationally (99th percentile; typical, unremarkable volume) the descriptor and the payment profile imply a volume-driven, low-margin testing line that dominates overall Medicare receipts. In contrast, the genomic panels (81440 at $3258 avg paid/claim and 81443 at $2400 avg paid/claim) are low-count but high-dollar contributors, consistent with a lab that pairs mass testing throughput with niche molecular diagnostics.
Overall payer mix is overwhelmingly Medicare-centric: lifetime Medicare revenue is $1.6M versus lifetime Medicaid revenue of $188, so the provider is effectively Medicare-dominant. Medicaid billing is negligible in scale relative to Medicare, indicating limited engagement with Medicaid-managed populations or low participation/volume in state programs.
Medicaid activity is concentrated entirely in K1034 where the provider reported 141 claims, $1 avg paid/claim, and $141 revenue, which the dataset lists as 100.0% of this provider’s total Medicaid revenue; this single-code Medicaid footprint ranks #4 of 5 in-state (25th percentile; typical, unremarkable volume). The Medicaid payments for COVID self-tests are minimal per claim, reinforcing that any Medicaid revenue is immaterial to the provider’s overall financial profile.
For specialized genomic tests the provider is a modest national participant: 81440 (56 claims, $182.4K revenue) ranks #9 of 13 providers nationally (33th percentile; typical, unremarkable volume) and 81443 (56 claims, $134.4K) ranks #9 of 14 (38th percentile; typical, unremarkable volume). Those rankings and small claim counts imply the lab performs these niche panels at a limited scale relative to specialty genomic labs, making it a minor player in those specific test markets despite meaningful per-claim reimbursements.
Numerous single-gene and smaller panels appear as tertiary Medicare contributors with small claim volumes and low percentile standings (examples include 81317: 27 claims, $17.9K revenue; 81298: 27 claims, $17K revenue; 81307: 24 claims, $15.9K revenue), each representing around 1% or less of Medicare revenue. This fragmentation suggests the lab offers a broad menu of molecular diagnostics but relies on a handful of codes for the bulk of revenue, which increases sensitivity to reimbursement or utilization shifts in those top codes.
The provider’s NPI was enumerated on 2023-02-27 (~3 years ago), indicating a relatively recent market entry; the combination of very large-volume COVID testing and a set of specialized genomic panels is consistent with a newer laboratory scaling volume-based services while selectively entering higher-revenue molecular niches. Given the short tenure and the concentrated revenue base, future growth or risk will likely hinge on sustaining K1034 volumes and maintaining referral flow for the genomic panels.
At the code-level the dataset repeatedly labels the provider’s volumes as "typical, unremarkable volume" even when national rank is high (for example K1034’s 99th percentile label), which suggests that the platform’s benchmarks treat COVID self-test distribution differently from specialty testing. Analysts should therefore interpret percentile and rank alongside absolute revenue and claim counts rather than relying solely on the percentile labels when assessing competitive strength.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 82,540 | $10 | $990.4K |
| 81440 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least 100 mitochondrial genes encoded in the nucleus, including 19 specific… | 60 | $3,260 | $182.4K |
| 81419 | The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in… | 60 | $2,400 | $134.4K |
| 81443 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least 15 genes, such as the 20 gene examples listed in the code descriptor. The… | 60 | $2,400 | $134.4K |
| 81448 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least five peripheral–neuropathy–related genes, such as the eight gene examples… | 60 | $570 | $32.1K |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 30 | $660 | $17.9K |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 30 | $630 | $17K |
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 20 | $660 | $15.9K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 30 | $590 | $14.7K |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 30 | $590 | $14.7K |
Showing 1–10 of 16
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 16 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
16 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81440 | 1 | 10 | 60 | $3,260 | $182.4K |
| 81443 | 1 | 10 | 60 | $2,400 | $134.4K |
| 81419 | 1 | 10 | 40 | $2,370 | $82.8K |
| K1034 | 5 | 420 | 260 | $10 | $68.9K |
| 81317 | 2 | 10 | 50 | $660 | $33.1K |
| 81307 | 2 | 10 | 50 | $660 | $32.5K |
| 81448 | 1 | 10 | 60 | $570 | $32.1K |
| 81238 | 2 | 10 | 50 | $590 | $28.8K |
| 81298 | 2 | 10 | 50 | $630 | $28.3K |
| 81249 | 2 | 10 | 40 | $580 | $25.6K |
Showing 1–10 of 16
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 140 | $1 | $140 |
How this provider's Medicaid billing volume and revenue compare to other Colorado providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Colorado median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 4 | 10 | 280 | $1 | $500 |
Other providers in the same ZIP code as Keystone Labs LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Arvada Fire Protection District | CO | Ambulance | $681.2K | $4.3M |
| Wayne Overman | CO | MOHS-Micrographic Surgery Physician | $366.6K | $0 |
| Rajiv Kumar | CO | Ophthalmology Physician | $159.7K | $0 |
| Jared Smedley | CO | Ophthalmology Physician | $158.6K | $0 |
| Annie Chang | CO | Ophthalmology Physician | $114.6K | $0 |
| Cynthia Tarkanian | CO | Ophthalmology Physician | $67.1K | $0 |
| Emily Messmer | CO | Family Nurse Practitioner | $61.5K | $0 |
| Ann Terry | CO | Hand Occupational Therapist | $17.3K | $0 |
| Kali Pearson | CO | Registered Dietitian | $1.2K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.